



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy Steroid-Eluting Sinus Stents

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 800

BCBSA Reference Number: 7.01.134

LCD/NCD: N/A

Related Policies

Balloon Sinuplasty for Treatment of Chronic Sinusitis, #582

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

The use of steroid-eluting sinus stents for postoperative treatment following endoscopic sinus surgery and for treatment of recurrent sinonasal polyposis is INVESTIGATIONAL.

The use of drug-eluting sinus stents is considered INVESTIGATIONAL in all other conditions.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed inpatient.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed outpatient.

	Outpatient
Commercial Managed Care (HMO and POS)	This is not a covered service.
Commercial PPO and Indemnity	This is not a covered service.
Medicare HMO Blue SM	This is not a covered service.
Medicare PPO Blue SM	This is not a covered service.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The following HCPCS code is considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

HCPCS Codes

CPT codes:	Code Description
C9122	Mometasone furoate sinus implant, 10 micrograms (sinuva)
J7401	Mometasone furoate sinus implant, 10 micrograms

Description

Chronic Rhinosinusitis

Chronic rhinosinusitis is an inflammatory sinus condition that has a prevalence between 1% and 5% in the U.S. population.¹

Treatment

Endoscopic sinus surgery (ESS) is typically performed on patients with chronic rhinosinusitis unresponsive to conservative treatment. The surgery is associated with high rates of improvement in up to 90% of more appropriately selected patients. However, there are no high-quality randomized controlled trials (RCTs) comparing functional ESS with continued medical management or alternative treatment approaches. Because of the high success rates and minimally invasive approach, these procedures have rapidly increased in frequency, with an estimated 250000 procedures performed annually in the United States.² They can be done either in the physician's office under local anesthesia or in the hospital setting under general anesthesia.

ESS involves the removal of small pieces of bone, polyps, and debridement of tissue within sinus cavities. There are a number of variations on the specific approach, depending on the disorders being treated and the preferences of the treating surgeon. For all procedures, there is substantial postoperative inflammation and swelling, and postoperative care is, therefore, a crucial component of ESS.

There are a number of postoperative treatment regimens, and the optimal regimen is uncertain. Options include saline irrigation, nasal packs, topical steroids, systemic steroids, topical decongestants, oral antibiotics, and/or sinus cavity debridement. Several RCTs have evaluated treatment options, but not all strategies have been rigorously evaluated.^{3,4,5,6} A 2011 systematic review has evaluated the evidence for these therapies.² Reviewers concluded that the evidence was not strong for any of these treatments but that some clinical trial evidence supported improvements in outcomes. The strongest evidence supported use of nasal saline irrigation, topical nasal steroid spray, and sinus cavity debridement.

Some form of sinus packing is generally performed postoperatively. Simple dressings moistened with saline can be inserted manually following surgery. Foam dressings are polysaccharide substances that form a gel when hydrated and can be used as nasal packs for a variety of indications.⁷ Middle meatal spacers are splint-like devices that prop open the sinus cavities post-ESS but are not designed for drug delivery. There is some RCT evidence that middle meatal spacers may reduce the formation of synechia following ESS, although the available studies have significant heterogeneity in this outcome.⁸

Implantable Sinus Stents

Implantable sinus stents are another option for postoperative management following ESS. These implants are intended to stabilize the sinus openings and the turbinates, reduce edema, and/or prevent obstruction by adhesions. They can also be infused with medication delivered topically over an extended period of time, and this local delivery of medications may be superior to topical applications in the postoperative setting.

Summary

Steroid-eluting sinus stents are devices used postoperatively following endoscopic sinus surgery (ESS) or for treatment of recurrent sinonasal polyposis following ESS. These devices maintain patency of the sinus openings in the postoperative period, and/or serve as a local drug delivery vehicle. Reducing postoperative inflammation and maintaining patency of the sinuses may be important in achieving optimal sinus drainage and may impact recovery from surgery and/or reduce the need for additional surgery.

For individuals who have chronic rhinosinusitis who have undergone ESS who receive implantable steroid-eluting sinus stents, the evidence includes randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in disease status, morbid events, and treatment-related morbidity. The most direct evidence relating to use of steroid-eluting nasal stents as an adjunct to ESS comes from 4 RCTs comparing steroid-eluting stents with either a non-steroid-eluting stent or medical management. The need for post-operative intervention at 30 days was reduced by 14% to 24%, translating to a number needed to treat of 4.7 or more. Three trials used blinded assessors to evaluate post-implantation sinus changes, an important strength, but the trials had potentials for bias. To most accurately evaluate the benefit from PROPEL devices it is important to ensure that the comparison group is not undertreated (ie, receives some form of packing, intranasal steroids, and irrigation). The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have recurrent sinonasal polyposis who have undergone ESS who receive implantable steroid-eluting sinus stents, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, and treatment-related morbidity. Two RCTs were identified evaluating the use of steroid-eluting nasal stents for recurrent or persistent nasal polyposis after ESS, which demonstrated improvements in polyp grade and ethmoid obstruction. Strengths of these trials included use of sham control and adequate power for its primary outcome. However, the trials had a high-risk of bias due to unblinded outcome assessment. Although avoidance of repeat ESS and oral steroids may be relevant outcomes for this indication, it would be more important if decisions about repeat ESS or other treatments were standardized and, in the trial setting, if decisions were prespecified or made by a clinician blinded to treatment group. Sinus stents may prove to have a role in nasal polyposis; however, further follow-up is needed to evaluate the durability of the results. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy History

Date	Action
7/2020	Clarified coding information
4/2020	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
10/2019	Clarified coding information.
4/2019	BCBSA National medical policy review. Ongoing Investigational statements clarified. Title changed to reflect the currently available steroid-eluting stents. Effective 4/1/2019.
1/2019	Clarified coding information.
3/2018	New references added from BCBSA National medical policy. Background and summary clarified.
7/2016	BCBSA National medical policy review. Investigational policy statement added for the use of sinus stents for recurrent sinonasal polyposis. Sinus Disease added to title. Effective 7/1/2016.
1/2016	Clarified coding information.

12/2014	New references added from BCBSA National medical policy.
1/2014	BCBSA National medical policy review. Removed “spacers” language throughout policy for consistency.
8/2013	New references from BCBSA National medical policy.
2/04/2013	New policy describing ongoing non-coverage.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Sedaghat AR. Chronic rhinosinusitis. Am Fam Physician. Oct 15 2017;96(8):500-506. PMID 29094889
2. Rudmik L, Soler ZM, Orlandi RR, et al. Early postoperative care following endoscopic sinus surgery: an evidence-based review with recommendations. Int Forum Allergy Rhinol. Nov-Dec 2011;1(6):417-430. PMID 22144050
3. Berlucchi M, Castelnuovo P, Vincenzi A, et al. Endoscopic outcomes of resorbable nasal packing after functional endoscopic sinus surgery: a multicenter prospective randomized controlled study. Eur Arch Otorhinolaryngol. Jun 2009;266(6):839-845. PMID 18946677
4. Cote DW, Wright ED. Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. Laryngoscope. Jun 2010;120(6):1269-1273. PMID 20513050
5. Freeman SR, Sivayoham ES, Jepson K, et al. A preliminary randomised controlled trial evaluating the efficacy of saline douching following endoscopic sinus surgery. Clin Otolaryngol. Oct 2008;33(5):462-465. PMID 18983380
6. Rotenberg BW, Zhang I, Arra I, et al. Postoperative care for Samter's triad patients undergoing endoscopic sinus surgery: a double-blinded, randomized controlled trial. Laryngoscope. Dec 2011;121(12):2702-2705. PMID 21997904
7. Rudmik L, Mace J, Mechor B. Effect of a dexamethasone Sinu-Foam™ middle meatal spacer on endoscopic sinus surgery outcomes: a randomized, double-blind, placebo-controlled trial. Int Forum Allergy Rhinol. Jan 17 2012;2(3):248-251. PMID 22253199
8. Lee JM, Grewal A. Middle meatal spacers for the prevention of synechiae following endoscopic sinus surgery: a systematic review and meta-analysis of randomized controlled trials. Int Forum Allergy Rhinol. Nov 2012;2(6):477-486. PMID 22648984
9. Huang Z, Hwang P, Sun Y, et al. Steroid-eluting sinus stents for improving symptoms in chronic rhinosinusitis patients undergoing functional endoscopic sinus surgery. Cochrane Database Syst Rev. Jun 10 2015;6(6):CD010436. PMID 26068957
10. Murr AH, Smith TL, Hwang PH, et al. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. Int Forum Allergy Rhinol. Jan-Feb 2011;1(1):23-32. PMID 22287304
11. Marple BF, Smith TL, Han JK, et al. Advance II: a prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants. Otolaryngol Head Neck Surg. Jun 2012;146(6):1004-1011. PMID 22301107
12. Smith, TT, Singh, AA, Luong, AA, Ow, RR, Shotts, SS, Sautter, NN, Han, JJ, Stambaugh, JJ, Raman, AA. Randomized controlled trial of a bioabsorbable steroid-releasing implant in the frontal sinus opening.. Laryngoscope, 2016 Jul 2;126(12). PMID 27363723
13. Luong, AA, Ow, RR, Singh, AA, Weiss, RR, Han, JJ, Gerencer, RR, Stolovitzky, JJ, Stambaugh, JJ, Raman, AA. Safety and Effectiveness of a Bioabsorbable Steroid-Releasing Implant for the Paranasal Sinus Ostia: A Randomized Clinical Trial.. JAMA Otolaryngol Head Neck Surg, 2017 Nov 4. PMID 29098299

14. Xu JJ, Busato GM, McKnight C, et al. Absorbable steroid-impregnated spacer after endoscopic sinus surgery to reduce synechiae formation. *Ann Otol Rhinol Laryngol*. Mar 2016;125(3):195-198. PMID 26391092
15. Han JK, Forwith KD, Smith TL, et al. RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis. *Int Forum Allergy Rhinol*. Nov 2014;4(11):861-870. PMID 25266981
16. Kern, RR, Stolovitzky, JJ, Silvers, SS, Singh, AA, Lee, JJ, Yen, DD, Illoreta, AA, Langford, FF, Karanfilov, BB, Matheny, KK, Stambaugh, JJ, Gawlicka, AA. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps.. *Int Forum Allergy Rhinol*, 2018 Jan 20;8(4). PMID 29350840